|
Clinical trials are research studies to test new drugs
ortreatments. These studies compare treatments that are in use
today (standard treatments) with others that may be better. Before a
new treatment is used on people, it is studied in the lab. If lab
studies suggest it will work, the next step is to test its
value for patients. These human studies are called clinical trials.
Clinical trials are an important part of cancer care. Usually
when a
patient enrolls in a clinical trial, the cost of tests, procedures,
drugs, extra doctor visits and any research directly related to the
study itself is covered by the group that sponsors the clinical trial.
The sponsor of the clinical trial may be the government, a drug
company, the National Cancer Institute, or some other agency.
Sometimes a health plan may define clinical trials as
"experimental" or "investigational." When this happens, health
insurance may not cover some of the costs of what is actually routine
care. This routine care includes costs such as doctor visits, hospital
stays, and tests
or treatments that you would have needed even if you were not taking
part in a clinical trial.
It
is important that cancer patients have insurance that covers clinical
trials. Lack of insurance coverage can keep patients who might want to
be in a clinical trial from taking part in one. In one survey, 60% of
patients said they feared having their insurance denied as a major
reason for not signing up to take part in a clinical trial. Another
study found that there was only a slight increase in medical costs for
adult clinical trial patients when compared with patients who were not
in clinical trials.
Many states have enacted laws regarding clinical trials. The
tables below contain the most current information available about laws
and special agreements that require insurance plans to cover a
patient's medical expenses during a clinical trial.
Clinical trials laws
| State
(year of enactment),
bill number* and/or
citation |
Who is
required to pay? |
What
services or benefits are covered? |
Other
key criteria |
Arizona
(2000)
SB 1213
20-2328 |
Hospital
or medical service
corporations, benefit insurers,
health care service organizations, disability insurers, group
disability insurers, and accountable health plans |
Patient
care costs
associated with Phase I through IV approved cancer clinical trials
|
Clinical
trial must be
reviewed by an Institutional Review Board in
AZ.
Health professional must agree to accept reimbursement from insurer as
payment in full.
Only covers study when no clearly superior non-investigational
treatment exists.
Clinical trial must be in AZ. |
California
(2000)
SB 37
|
All
California insurers,
including Medicaid and other medical assistance programs |
Patient
care costs
associated with Phase I through IV approved cancer clinical trials |
May
restrict coverage to
services in CA. |
Colorado
(2009)
HB 09-1059
|
All
individual and group
health insurers, including HMO, operating in
Colorado |
Routine
care costs: if the
doctor believes the patient may
benefit from the clinical trial; the trial is approved under Medicare;
care is provided by licensed, registered, or certified providers; and
the patient has a disabling, progressive, or life-threatening
condition. |
Insurers
may exclude
coverage for: --Any part of a trial
paid for by a government or commercial sponsor, including any drug or
device paid for by others
-- Housing and travel expenses
--Any item or service used solely to collect or analyze data not
directly related to the patient's care
-- Trial management costs
--Any health care services specifically excluded under the patient's
benefit plan |
Connecticut
(2001)
SB 325
Public Act 01-171 |
Private
insurers,
individual and group health plans
|
Patient
care costs
associated with approved cancer clinical trials
|
Prevention
clinical trials
are covered only in Phase III and only if
they involve therapeutic intervention.
Insurer may require documentation of the likelihood of therapeutic
benefit, informed consent, protocol information, and/or summary of
costs. |
Delaware
(2001)
SB 181
|
Every
group of blanket
policy, including policies or contracts issued
by health service corporations |
Patient
care costs for
covered persons
in approved clinical trials for the treatment of life-threatening
diseases under specified conditions |
Clinical
trial must have
therapeutic intent and enroll individuals diagnosed with the disease.
Clinical trial must not be designed exclusively to test toxicity or
disease pathophysiology. |
District
of Columbia (2008)
Bill 17-469
(D.C. Law 17-166)
|
All
insurers in D.C. |
Routine
patient care costs
for people in
approved clinical trials undertaken for prevention, early detection,
treatment, or monitoring of cancer |
Insurers
are not required
to cover
or reimburse:
--Tests or measurements done mainly for the purpose of the clinical
trial involved
--Services or products provided only to collect or analyze data
--Services or products given free of charge to trial participants by
the research sponsors |
Georgia
(1998)
SB 603,
Act 801
|
All
insurers and the state
health plan |
Patient
care costs
associated
with Phase II and III of approved prescription drug clinical trial
programs for the treatment of children’s cancer |
The
child has to have
been diagnosed with cancer prior to his or her 19th birthday, and the
trial has to have been approved by the FDA or the NCI |
Indiana
(2009)
HB 1382
Public Law 109 |
State
employee health
plans, the state Medicaid
program, policies of accident and sickness insurance, and HMO contracts
|
Patient
care costs
associated with approved Phase I through IV cancer
clinical trials if the insurer would provide coverage for the same
routine care costs if they were not incurred in a
clinical trial |
There
must be no clearly
superior, non-investigational
alternative care method; and data must show that the care method used
in the research study is likely to work as well as approved care. With
slight variations for Medicaid, health plans may exclude coverage for:
--The service, item, or drug that is being tested --Treatments that are
not part of the usual and customary standard of care --Health care
services, items, or drugs used solely for data collection or analysis
and not in the direct care of the patient --Investigational drugs or
devices not approved by FDA -- Travel, food, and lodging -- Services,
items, or drugs provided by the clinical trial sponsors --Services,
items, or drugs that are eligible for reimbursement from other sources |
Louisiana
(1999)
RS 22:230.4
SB 761 |
HMOs,
PPOs, State Employee
Benefits Program, and other
specified insurers |
Patient
care costs
associated with Phase II through
IV approved cancer clinical trials
|
Only
covers costs when no
clearly superior, non-investigational
approach exists.
Available data must support reasonable expectation that the treatment
will be as effective as the non-investigational alternative.
Institutional Review Board-approved consent form must be used. |
Maine
(2000)
24-A-4310 |
Managed
care organizations
and private insurers |
Patient
care costs associated with an approved clinical trial
|
Participation
must offer
meaningful potential for significant clinical
benefit. Referring physician must conclude that trial participation is
appropriate. |
+Maryland
(1998)
SB 137
HB 45
Chap 146-15-827 |
Private
insurers and other
specified managed care
organizations |
Patient
care costs
associated with approved Phase I
through IV cancer treatment, supportive care, early detection, and
prevention trials; Phase II through IV for other life-threatening
conditions; and Phase I considered on a case-by-case basis
|
There
is no clearly
superior, non-investigational alternative.
The data provide a reasonable expectation that the treatment will be as
least as effective as the alternative. |
Massachusetts
(2002)
HB 4376 (Chap 257)
Chap 176A Sec 8X |
All
health plans issued or
renewed after Jan. 1, 2003
|
Patient
care costs
associated with all phases of approved cancer
clinical trials |
Insurers
must provide
payment for services that are
consistent with the usual and customary standard of care provided under
the trial’s protocol and that would be covered if the patient
did not
participate in the trial. |
Missouri
(2002)
SB 1026
376.429
(2006) - Phase II
SB 567 and 792 |
All
health benefit plans
operating in the state
|
Patient
care costs
associated with approved Phase II, III, or IV
clinical trials for the prevention, early detection, or treatment of
cancer |
There
must be identical or
superior non-investigational
treatment alternatives available before providing clinical trial
treatment, and there must be a reasonable expectation that the study
will be superior to the alternatives.
Requires coverage of FDA-approved drugs and devices even if they have
not been approved for use in treatment of patient’s
particular
condition.
Health benefit plans may limit coverage of routine care costs of
patients in phase II trials to those facilities within the plans'
provider network. (For individually underwritten health plans, the
phase II provision is not mandatory but must be offered as an option.) |
Nevada
(2003, amended 2005)
SB 29
NRS 695G.173 |
All
private insurers and
managed care plans
|
Patient
costs associated
with approved Phase I through IV cancer
clinical trials
|
Health
care facility and
staff must have experience and training to
provide the treatment in a capable manner.
There must be no medical treatment available which is considered a more
appropriate alternative medical treatment than the medical treatment
provided in the clinical trial.
There must be a reasonable expectation based on clinical data that the
medical treatment provided in the clinical trial or study will be at
least as effective as any other medical treatment.
The trial must be conducted in Nevada. |
New
Hampshire (2000)
SB 409
415:18 |
Private
insurers and
specified managed care plans |
Patient
care
costs associated with approved Phase I through IV trials for cancer and
other life-threatening conditions, with coverage for Phase I and II
trials to be decided on a case-by-case basis.
Coverage is also required for reasonable and medically necessary
services to administer the drug or device under evaluation in the
clinical trial. |
Clinical
trials are
covered when standard treatment
has been or would be ineffective or does not exist, or when there is no
clearly superior non-investigational alternative. |
New
Mexico (2002, 2009)
SB 240
59A-22-43
SB 42, Chapter 212 |
Private
insurers, specified
managed care plans, and
Medicaid or other state medical assistance programs; group health
coverage, including any form of self-insurance,
offered, issued or renewed under the Health Care Purchasing Act
|
Patient
care costs
associated with the patient's participation in an
approved Phase I through IV cancer clinical trial
|
The
clinical trial must be
undertaken for the purposes of preventing
cancer recurrence, early detection, or treatment of cancer for which
there is no equally or more effective standard cancer treatment. The
trial must have therapeutic intent. There must be a reasonable
expectation that treatment will be at least as effective as standard or
non-investigational cancer treatment. Payment is limited to in-state or
in-network costs, unless the plan covers standard out-of-state or
out-of-network treatment. |
North
Carolina (2001)
SB 199
58-3-255 |
All
health insurance plans
and teachers and state employees'
comprehensive major medical plan
|
Patient
care costs
associated with approved Phase II through IV
clinical trials
|
Patients
suffering from a
life-threatening disease or chronic
condition may designate a specialist who is capable of coordinating
their health care needs.
Ohio (2008)
SB 186
ORC Ann. 1751.01 All health benefit plans including those for public
employees
Medically necessary costs of health care services associated with any
stage of an approved clinical trial
Insurers do not have to cover services or products that are part of the
investigative trial; any item or procedure used only for data
collection for the trial; any item not approved by FDA; and food,
lodging, and transportation related to travel for participation in the
trial. |
Oregon
(2010)
SB 316 Chapter 274 |
All
individual and group
health benefit plans,
including HMOs |
Patient
care costs
associated with approved Phase I
through IV cancer clinical trials that would be covered by the health
benefit plan outside of a clinical trial |
Patients
taking part in
covered clinical trials pay the same deductibles, co-pays,
co-insurance, and other fees associated with their care that they would
pay if they were not taking part in a clinical trial. |
Rhode
Island (1994, 1997)
94-SB 2623
97-SB 1,
HB 5062 |
Private
insurers and
specified managed care plans |
Patient
care costs
associated with approved Phase II through IV cancer clinical trials |
|
Tennessee
(2005)
HB 837 |
All
health benefit plans
offered by an employer |
Patient
care
costs associated with approved Phase I through IV cancer clinical
trials |
The
subject of the trial
must evaluate a drug, medical device,
or service that falls within a Medicare benefit category. Limits
coverage to those drugs, medical devices, and services that have been
approved by the FDA and that are used in the clinical management of the
patient. |
Texas
(2009)
SB 39, Chapter 719 |
All
individual and group
health benefit plans,
including HMOs, state Medicaid and Medicaid managed care organizations
(to the extent allowed by federal law), and state employee health
benefit plans that are issued or renewed on or after January 1, 2010
|
Patient
care costs
associated with approved Phase I through IV
clinical trials are covered provided that they are conducted to
prevent, detect, or treat a life-threatening disease or condition
|
Routine
patient care costs
means the costs of medically necessary
health care services that would be covered by the health benefit plan
outside of a clinical trial, except for the costs of: -- Drugs or
devices not approved by the FDA, including the drug or device being
studied
-- Nonhealth care services
-- Health care services that are specifically excluded from coverage
under a health plan.
Research institutions and health care professionals must accept
reimbursement at insurers' usual rates as payment in full for routine
patient care. Insurers do not have to pay for services that are part of
the subject matter of the clinical trial, which are usually paid for by
the research institution conducting the trial. Insurers are not
required to provide benefits for: --Routine care provided outside of
the plan's provider network, unless the plan normally covers
out-of-network benefits --Health care services provided outside of
Texas, unless the plan normally covers out-of-state health care
services. Patients taking part in covered clinical trials pay the same
deductibles, co-pays, co-insurance, and other fees that they would pay
if they were not in a clinical trial. Insurers cannot cancel or refuse
to renew coverage under a plan solely because an enrollee in the plan
takes part in a clinical trial. |
Vermont
(2001, amended 2005
to remove March 1, 2005 sunset
provision)
Chap 107 4088b
HB 6 |
All
health insurance
policies and health benefit plans in the
state, including Medicaid |
Patient
care costs
associated with approved
cancer clinical trials conducted through a Vermont or New Hampshire
cancer care provider. If no suitable trial is available the law covers
approved cancer clinical trials being administered by a hospital and
its affiliated, qualified cancer care providers outside New Hampshire
or Vermont
|
Participants
in cancer
trials located outside Vermont must provide
notice to the health benefit plan prior to their participation. Health
insurers may require patients taking part in a trial outside the
provider network to get routine follow-up care within the plan's
network, unless the patient's cancer care provider determines this
would not be in the best interest of the patient.
Providers and insurers must take part in a cost analysis to determine
impact of the program on health insurance premiums. |
Virginia
(1999)
SB 1235
HB 871
38.2-3418.8 |
Private
insurers, specified
managed care plans, and public employee health plans |
Patient
care costs
associated with approved Phase II through IV cancer clinical trials;
Phase I coverage is provided on a case-by-base basis
|
There
must be no clearly
superior, non-investigational alternative.
Data must provide a reasonable expectation that the treatment will be
as least as effective as the alternative. |
West
Virginia (2003)
HB 2675
9-2-12 |
Private
insurers, managed
care plans, Medicaid or state medical
assistance, public employee health plans
|
Patient
care costs
associated with approved Phase II through IV
clinical trials for the prevention, early detection, or treatment of
cancer or any other life-threatening condition
|
Facility
and staff
providing the treatment are capable of doing so by
virtue of their training, experience, and volume of patients treated to
maintain expertise.
The treatment must have therapeutic intent.
There must be no clearly superior, non-investigational treatment
alternative.
Data provide a reasonable expectation that the treatment will be more
effective than the non-investigational treatment alternative. |
Wisconsin
(2006)
AB 617
Act 194
|
Any
health insurance plan
operating in the state, and any self-insured
plans |
Patient
care costs
associated with all phases of approved cancer
clinical trials |
Trial
must intend to
improve the trial participant's
health outcomes and not be designed only to test toxicity or disease
pathophysiology. |
Wyoming
(2008)
SF 0024
|
All
health insurance
policies, contracts, and certificates that cover
any Wyoming resident
|
Patient
care costs
associated with approved Phase II, III, or IV
clinical trials for cancer treatment |
The
medical treatment must
be
given by a licensed health care provider operating within the scope of
his/her license in a facility whose staff has the experience and
training necessary to provide competent treatment. The patient must
have signed an informed consent before starting the clinical trial. |
*SB = Senate bill; HB = House bill.
+Additional Maryland
information: A 2003 Maryland law (S 128)
repealed a reporting requirement for insurers, non-profit health
service plans, and HMOs to submit a report that described the trials
covered during the previous year.
(Table adapted
from National Conference of State Legislatures
©, 2010)
Special agreements
| State
(year agreement
became effective) |
Who is
required to pay? |
What
services or benefits are covered? |
Other
key criteria |
| Georgia
(2002)
Georgia Cancer Coalition |
All
major insurers |
Routine patient care
costs associated with approved Phase I through IV clinical trials for
cancer patients and recommended by a treating physician. Coverage of
cancer screenings and exams that follow the most recently published
guidelines and recommendations from any nationally recognized health
care organization. |
The
clinical trial must either (1) involve a drug
that is currently exempt under federal regulations from a new drug
application or (2) be a trial that is approved by one of the specified
federal agencies or a local institutional review board. |
| Michigan (2002)
Michigan Consensus Agreement |
Private
insurance plans, HMOs, and
Medicaid |
Routine patient care costs
associated with approved Phase II
and III cancer clinical trials. |
Coverage
for Phase I clinical trials
is under consideration |
| Nebraska
(2009)
Nebraska Insurance Federation Agreement |
Health
benefit providers who
are members of the Nebraska Insurance Federation have voluntarily
agreed to provide this coverage as part of health insurance contracts
that they underwrite |
Routine
patient care costs associated with
approved Phase II through IV clinical trials
|
Routine patient care costs
means the costs associated with health care
services that would be covered by the health plan outside of a clinical
trial, including items or services that are typically covered by the
plan outside of a clinical trial. It excludes the investigational item
or service itself, unless it would be covered outside of the clinical
trial items; services needed only to collect data or determine
eligibility; or services that would be paid for by the trial sponsor in
the absence of insurance coverage. Deductibles or co-pays may apply to
routine patient care costs in a clinical trial, subject to the terms of
the patient's benefit plan. Members of the Nebraska Insurance
Federation reserve the right to review the administration and efficacy
of this agreement and may modify or terminate it. |
| New Jersey (1999)
New Jersey Consensus Agreement |
All
insurers |
Routine
patient care costs associated with all phases of cancer clinical trials |
|
| Ohio
(1999)
Ohio Med Plan |
State
employees on Ohio Med Plan |
Routine patient care
costs associated with approved Phase II and III cancer treatment
clinical trials |
Pre-authorization
is required for clinical trial
participation. |
(Table
adapted from National Conference of State Legislatures
©, 2010)
These special agreements are made between the state and the
insurance companies to voluntarily provide coverage for clinical
trials. They are not like the laws, which say what types of coverage
must be provided. Special agreements vary from state to state. To learn
more, contact your state insurance department. (See the section, "How
to find out more about your health plan's clinical trial coverage.")
Approved clinical trials and other state
requirements
Some states require certain agencies to approve a clinical
trial before the insurance company is required to cover related
expenses. Examples of these approval agencies are:
- National Institutes of Health (NIH)
- NIH cooperative group or center
- National Cancer Institute (NCI) cooperative group or center
- The Coalition of National Cancer Cooperative Groups
- US Food and Drug Administration (FDA)
- US Department of Defense
- US Department of Veterans Affairs
More detailed information on your state's coverage
requirements, including the lists of agencies that must approve the
clinical trial, and links to some of the legislative documents can be
found at the National Cancer Institute's "States That Require Health
Plans to Cover Patient Care Costs in Clinical Trials" list at www.cancer.gov/clinicaltrials/ctlaws-home#Anchor-33277.
Medicare and Medicaid coverage
Medicare
If you take part in an approved clinical trial, Medicare
covers routine costs for items and services, such as:
- doctor visits and tests
- room and board for a hospital stay that Medicare would pay
for even if you weren't in a study
- an operation to implant an item that is being tested
- treatment of side effects and problems caused by the new
care
In most cases, Medicare does not pay for these things:
- the experimental item or service being tested -- unless
Medicare would cover it even if you weren't in a clinical
trial
- items and services the study gives you for free
- items or services used only to collect data and not needed
as part of your direct health care, such as monthly CT scans for a
condition that usually requires one scan
- co-insurance and deductibles
Keep in mind that you will have to pay the part of the charge
that you would normally pay for Medicare covered services.
For more information, please call 1-800-633-4227
(1-800-MEDICARE).
Medicaid
Many state Medicaid programs cover all or some of the costs of
clinical trials. Coverage is determined by each state, but many follow
guidelines much like those listed above for Medicare. Contact your
State Department of Health to find out the coverage in your state.
You can find the number of your state's health department in
the blue pages of your phone book or at the Centers for Disease Control
and Prevention Web site at www.cdc.gov/mmwr/international/relres.html.
Scroll down to "Medicaid - List of State Health Departments" and click
for an ABC list of states.
How
to find out more about your health plan's clinical trial coverage
If you are thinking about entering a clinical trial, you may
want to contact your state insurance department to learn the details of
any laws specific to your state. State insurance departments can also
take reports of insurance fraud, and can often give you more
information and the most up-to-date information about what is required
of your insurance company. You can find your state's insurance
department in the blue pages of your local phone book, or visit the
Web site of the National Association of Insurance Commissioners at www.naic.org/state_web_map.htm.
Living in a state that does not require clinical trials
coverage doesn't mean your insurance provider will not offer coverage.
It is always a good idea to contact your insurer to find out what they
will cover before you get involved in a clinical trial.
If you have more questions about your state coverage and
clinical trials, contact the American Cancer Society's clinical trials
team directly at 1-800-303-5691. They can help answer your questions
about your state's health insurance coverage of clinical trials.
Additional resources
More information from your American Cancer
Society
The following information may also be helpful to you. These
materials may be ordered from our toll-free number, 1-800-ACS-2345
(1-800-227-2345).
National organizations and Web sites
Along with the American Cancer Society, other sources of
information and support include:
Centers for
Medicare & Medicaid Services (CMS) - HHS
Toll-free number: 1-800-633-4227 (1-800-MEDICARE)
TTY: 1-877-486-2048
Web site: www.cms.hhs.gov
Has complete and up-to-date information on Medicare and can give you
contact information for Medicaid and State Children’s Health
Insurance Program (SCHIP), which are state-run programs
National
Association of Insurance Commissioners (to find your
state's Department of Insurance)
Toll-free number: 1-866-470-6242
Web site: www.naic.org/state_web_map.htm
Provides a map of the United States to find your state's Commissioner
of Insurance/Insurance department
National Cancer
Institute
Toll-free number: 1-800-422-6237 (1-800-4-CANCER)
Web site: www.cancer.gov
For accurate, up-to-date information about cancer for patients, their
families, and the general public; also provides information on
understanding clinical trials, deciding whether to take part in trials,
finding specific trials, plus research news, and other resources
No matter who you are, we can help. Contact us anytime, day or
night, for information and support. Call us at 1-800-227-2345 or
visit www.cancer.org.
References
American Cancer Society Cancer Action Network. How Do You Measure Up? A
Progress Report on State Legislative Activity to Reduce Cancer
Incidence and Mortality. July 2009.
Centers for Medicare and Medicaid Services. Medicare and
Clinical Research Studies. Accessed at
www.medicare.gov/Publications/Pubs/pdf/02226.pdf on February 10, 2010.
National Association of Insurance Commissioners. State
Insurance Department Websites. Accessed at
www.naic.org/state_web_map.htm on February 10, 2010.
National Cancer Institute. State Cancer Legislative Database
Program. Accessed at www.scld-nci.net/index.cfml on February 10, 2010.
National Cancer Institute. States That Require Health Plans to
Cover Patient Care Costs in Clinical Trials. Accessed at
www.cancer.gov/clinicaltrials/ctlaws-home#Anchor-33277 on February 10,
2010.
National Conference of State Legislatures. Clinical Trials: What are States
Doing? August 2009 Update. Accessed at
www.ncsl.org/IssuesResearch/Health/ClinicalTrialsWhatareStatesDoing2008/tabid/14331/Default.aspx
on February 10, 2010.
Last Medical Review: 02/24/2010
Last Revised: 02/24/2010
|